

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-256.2CIPUS

In Re Application Of: SALMAN et al.

JUL 3 0 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/552,503	6/8/2006	Unknown	26,815	1614	2262

Title: AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-256.2CIPUS

In Re Application of: **SALMAN et al.**

JUL 30 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/552,503	6/8/2006	Unknown	26,815	1614	2262

Title: **AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

 (Date)

 Signature

George E. Heibel, Esq.
 Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account,

G.E.H.
 Signature

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

July 27, 2007

Christine Kenedy-Renner
 Signature of Person Mailing Correspondence

Christine Kenedy-Renner

Typed or Printed Name of Person Mailing Certificate

George E. Heibel, Esq.
 Reg. No. 42,648

CUSTOMER NO. 26,815

CC:

INFORMATION DISCLOSURE CITATION <small>JUL 30 2007</small> <small>SUPPLEMENTAL</small>				Docket No.: RLL-256.2CIPUS	Serial No.: 10/552,503	
				Applicants: MEHTA et al.		
				Filed: 10/7/2005	Group:	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/G.S./	S1A1	5,179,108	1/12/1993	George et al.	514	319	
	S1A2	2003/0105071	6/5/2003	Cuny et al.	514	210.2	
	S1A3	2003/0162780	8/28/2003	Brotherton-Pleiss et al.	514	235.5	
	S1A4	2003/0171362	9/11/2003	Madera et al.	514	218	
↓	S1A5	7,232,835	6/19/2007	Mehta et al.	514	323	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/G.S./	S1B1	WO 99/43657	9/2/1999	PCT	C07D	211/26	
	S1B2	WO 01/47893	7/5/2001	PCT	C07D	221/24	
	S1B3	WO 01/090082	11/29/2001	PCT	C07D	241/08	
	S1B4	WO 03/033495	4/24/2003	PCT	C07D	453/02	
	S1B5	WO 03/048124	6/12/2003	PCT	C07D	211/26	
	S1B6	WO 03/048125	6/12/2003	PCT	C07D	211/58	
	S1B7	WO 04/067510	8/12/2004	PCT	C07D	209/52	
	S1B8	WO 04/069835	8/19/2004	PCT	C07D	471/08	
	S1B9	WO 04/089363	10/21/2004	PCT	A61K	31/403	
	S1B10	WO 04/089898	10/21/2004	PCT	C07D	209/52	
	S1B11	WO 04/089899	10/21/2004	PCT	C07D	209/52	
	S1B12	WO 2005/092341	10/6/2005	PCT	A61K	31/496	
	S1B13	WO 2005/003587	1/12/2006	PCT	A61K	9/16	
↓	S1B14	WO 2006/035282	4/6/2006	PCT	A61K	31/439	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION			Docket No.: RLL-256.2CIPUS	Serial No.: 10/552,503		
			Applicants: MEHTA et al.			
SUPPLEMENTAL			Filed: 10/7/2005	Group:		

/G.S./	S1B15	WO 2006/064304	6/22/2006	PCT	C07D	209/52	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/G.S./ ↓	s1C1	Kaiser et al, "Synthesis and Antimuscarinic Activity of Some 1-Cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , 36(5):610-616 (1993)
↓	s1C2	Carter et al, "Analogues of Oxybutynin. Synthesis and Antimuscarinic and Bladder Activity of Some Substituted 7-Amino-1-hydroxy-5-heptyn-2-ones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , 34(10):3065-3074 (1991)
↓	s1C3	Morissette et al, "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids", <i>Advanced Drug Delivery Reviews</i> , 56:275-300 (2004)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.S./

EXAMINER	/Golam Shameem/	DATE CONSIDERED	02/02/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			